Summary

The global Closed System Drug-Transfer Device CSTD market is projected to grow from US$ 1470 million in 2025 to US$ 2523 million by 2032, at a CAGR of 8.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Closed System Drug-Transfer Device CSTD refers to a specialized disposable drug-transfer system designed to reduce occupational exposure during the preparation, reconstitution, transfer and administration of antineoplastic and other hazardous drugs. The system maintains a closed fluid pathway through mechanical sealing, membrane interfaces, pressure-balancing structures, filtration or adsorption mechanisms, limiting the escape of hazardous drug liquids, aerosols and vapors while restricting environmental contaminants from entering the drug pathway. Commercial products are primarily configured as Closed Vial Access Devices, Closed Syringe Transfer Devices, Closed Bag and Line Access Devices and Integrated Closed Drug Transfer Systems. Core components typically include vial adapters, syringe-side connectors, infusion adapters, spikes and administration connectors. The market primarily serves oncology drug compounding, oncology infusion administration and other hazardous drug preparation environments, with demand concentrated in hospital pharmacy departments, oncology infusion facilities and specialized hazardous-drug handling settings.
Key Findings
Global CSTD sales volume is estimated at approximately 220 million units in 2025 and 236 million units in 2026
The blended global selling price is estimated at approximately US$6.7 per unit
Oncology drug compounding and infusion administration remain the principal consumption scenarios for CSTD products
North America and Western Europe represent mature adoption markets while Asia provides greater penetration-driven expansion potential
Market Trends
The Closed System Drug-Transfer Device CSTD industry is evolving from individual protective connectors toward more integrated vial-to-patient hazardous-drug protection systems. Product development increasingly emphasizes simplified connection procedures, ergonomic operation, leak-resistant membrane interfaces, lower residual drug volume and compatibility across multiple vial, syringe and infusion configurations. Physical barrier technology remains an important commercial design route, while air-cleaning approaches based on filtration or adsorption continue to serve selected system architectures. Hospital customers are increasingly evaluating CSTD platforms as complete workflow solutions rather than isolated adapters, encouraging manufacturers to expand product portfolios across drug preparation, transfer and administration. At the same time, pressure to improve workflow efficiency is increasing demand for systems that reduce connection steps and training complexity without compromising containment performance.
Market Dynamics
Drivers
Growth in Closed System Drug-Transfer Device CSTD consumption is primarily supported by increasing hazardous-drug handling volumes, continued expansion of oncology treatment activity and stronger occupational exposure controls for pharmacists, nurses and other healthcare professionals. The recurring disposable nature of vial adapters, syringe connectors and administration components creates a consumption model closely linked to drug-preparation frequency rather than installed equipment volume. Increasing institutional focus on hazardous-drug containment and standardized pharmacy procedures is also supporting wider integration of CSTD products into routine compounding and administration workflows.
Restraints
The principal restraints are the additional consumable cost relative to conventional drug-transfer components and the operational complexity created by multi-component systems. Hospitals must consider product compatibility, training requirements, workflow changes and procurement costs when adopting a CSTD platform. Price sensitivity is particularly significant in emerging healthcare markets, where conventional transfer devices remain widely used. Differences in connector architecture between manufacturers can also increase switching costs and limit interoperability, while high-volume hospital tenders place continuing pressure on realized selling prices.
Opportunities
The strongest opportunities are concentrated in markets where hazardous-drug handling volumes are expanding but CSTD penetration remains below mature-market levels. Asia represents an important opportunity as oncology capacity, centralized intravenous admixture services and occupational safety practices continue to develop. Product opportunities are also emerging around easier-to-use integrated systems, broader vial and infusion compatibility and workflow designs suitable for both centralized pharmacy compounding and ambulatory infusion. Regional manufacturing and localized supply chains may further improve product affordability and support adoption in price-sensitive healthcare systems.
Challenges
The CSTD industry faces continuing challenges in demonstrating containment performance across different hazardous drugs, operating conditions and clinical workflows. Manufacturers must balance sealing performance, connection force, ergonomics, residual volume and compatibility within the same product architecture. Market fragmentation across proprietary connector designs can complicate hospital standardization, while new entrants require significant regulatory, manufacturing-quality and clinical-validation capabilities before achieving institutional acceptance. Competitive pressure is therefore increasingly determined not only by product price but also by evidence quality, workflow reliability, supply continuity and the ability to support large hospital systems.
Industry Chain Analysis
The upstream industry chain consists primarily of medical-grade engineering polymers, elastomeric sealing materials, membranes, filters, activated adsorption materials, stainless-steel or polymeric cannula components, molding tooling and sterile medical packaging. Manufacturing requires high-precision injection molding, automated assembly, cleanroom production, leak and pressure testing, sterilization and quality-control capabilities. Because CSTD performance depends heavily on sealing tolerances and repeatable connection interfaces, tooling precision, component consistency and automated assembly capability are important determinants of manufacturing quality and cost.
The midstream comprises manufacturers responsible for complete CSTD product design, regulatory compliance and commercial supply. Value creation is concentrated in containment technology, connector architecture, system compatibility, manufacturing automation and validated hazardous-drug performance. Downstream customers include hospital pharmacies, oncology centers, infusion facilities and other organizations handling hazardous drugs. The recurring nature of disposable components gives the market a high proportion of repeat consumable revenue, while procurement economics are influenced by hospital volume, component mix, regional pricing and whether customers adopt individual components or an integrated system platform.
Segment Insights
By product type, the market is structured around Closed Vial Access Devices, Closed Syringe Transfer Devices, Closed Bag and Line Access Devices and Integrated Closed Drug Transfer Systems. Vial-side products address drug reconstitution and withdrawal, syringe-side components maintain containment during transfer, and bag and line devices extend the closed pathway into infusion preparation and administration. Integrated systems increasingly strengthen supplier positioning because hospitals can standardize multiple steps of hazardous-drug handling around a single connection architecture.
By technology type, Physical Barrier Technology and Air Cleaning Technology represent the two high-confidence commercial approaches, with other less standardized designs grouped under Other. Physical barrier systems rely on sealed mechanical interfaces, membrane-to-membrane connections or pressure-balancing structures, while air-cleaning designs use filtration or adsorption mechanisms to control contaminated air or drug vapor. Future product differentiation is expected to focus more on containment performance, ease of connection, workflow efficiency and compatibility than on adding narrowly defined technology subclasses.
Downstream Market Opportunities
Oncology Drug Compounding and Oncology Infusion Administration remain the most important downstream opportunities because antineoplastic drugs are frequently prepared, transferred and administered through repeated multi-step workflows. Hazardous Drug Pharmacy Preparation provides an additional addressable field beyond oncology, while Ambulatory Infusion Centers create opportunities for systems that combine containment with simplified handling and lower workflow complexity. The most attractive incremental demand is expected where centralized hazardous-drug preparation expands and institutions standardize CSTD use across both pharmacy preparation and patient administration.
Regional Insights
North America is the most mature CSTD market, supported by established hazardous-drug safety practices, large oncology treatment volumes and broad institutional familiarity with closed transfer systems. Western Europe also represents a mature commercial region, although hospital tendering and centralized procurement can create stronger price pressure. Israel has strategic importance on the supply side because several specialized global CSTD manufacturers originate there, while Japan maintains an established domestic medical-device manufacturing base and has seen additional CSTD product development.
Asia offers greater penetration-driven opportunity, particularly in China and other markets where oncology infrastructure and centralized drug-compounding capacity continue to expand. China is also developing a domestic manufacturing base, increasing the likelihood of localized products competing on cost, supply responsiveness and hospital compatibility. Singapore and China Taiwan provide additional specialized manufacturing capabilities, while Korea and India currently represent more significant application and distribution markets than core global CSTD manufacturing clusters.
Competitive Landscape Analysis
The Closed System Drug-Transfer Device CSTD market combines large international medical-device groups with specialist hazardous-drug transfer manufacturers and emerging regional suppliers. Becton Dickinson and Company and ICU Medical benefit from established global infusion and hospital-channel capabilities, while EQUASHIELD Medical and Simplivia Healthcare maintain specialist positioning built around dedicated CSTD portfolios. Terumo Corporation, Vygon SAS and JMS Co. Ltd. extend competition through broader infusion and medical-consumable capabilities, while Yukon Medical, CORMED, Epic Medical, Haemopharm Healthcare and SIDAM provide specialized or regional alternatives. Chinese manufacturers including Shandong Ande Healthcare Apparatus, the PW Medtech manufacturing system and Wuhan Zhixun Chuangyuan are expanding the domestic supply base. Competition increasingly centers on containment performance, product-system completeness, clinical workflow compatibility, manufacturing quality, regulatory credentials, hospital relationships and the ability to maintain reliable high-volume consumable supply.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Closed System Drug-Transfer Device CSTD market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Becton Dickinson and Company
ICU Medical Inc.
EQUASHIELD Medical Ltd.
Simplivia Healthcare Ltd.
Terumo Corporation
JMS Co. Ltd.
Vygon SAS
CODAN Medizinische Geräte GmbH
Yukon Medical LLC
CORMED Inc.
Epic Medical Pte. Ltd.
Haemopharm Healthcare S.r.l.
SIDAM S.r.l.
Daiwa Can Company
Shinva Ande Healthcare Apparatus Co. Ltd.
Beijing Fert Technology Co. Ltd.
Wuhan W.E.O. Science and Technology Development Co. Ltd.
CHI FENG CO. LTD.
Segment by Type
Closed Vial Access Device
Closed Syringe Transfer Device
Closed Bag and Line Access Device
Integrated Closed Drug Transfer System
Segment by Technology Type
Physical Barrier Technology
Air Cleaning Technology
Other
Segment by Application
Oncology Drug Compounding
Oncology Infusion Administration
Hazardous Drug Pharmacy Preparation
Ambulatory Infusion Center
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Closed System Drug-Transfer Device CSTD study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Closed System Drug-Transfer Device CSTD: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Closed System Drug-Transfer Device CSTD Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Closed Vial Access Device
1.2.3 Closed Syringe Transfer Device
1.2.4 Closed Bag and Line Access Device
1.2.5 Integrated Closed Drug Transfer System
1.3 Market Segmentation by Technology Type
1.3.1 Global Closed System Drug-Transfer Device CSTD Market Size by Technology Type, 2021 vs 2025 vs 2032
1.3.2 Physical Barrier Technology
1.3.3 Air Cleaning Technology
1.3.4 Other
1.4 Market Segmentation by Application
1.4.1 Global Closed System Drug-Transfer Device CSTD Market Size by Application, 2021 vs 2025 vs 2032
1.4.2 Oncology Drug Compounding
1.4.3 Oncology Infusion Administration
1.4.4 Hazardous Drug Pharmacy Preparation
1.4.5 Ambulatory Infusion Center
1.4.6 Other
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Closed System Drug-Transfer Device CSTD Revenue Estimates and Forecasts (2021-2032)
2.2 Global Closed System Drug-Transfer Device CSTD Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Closed System Drug-Transfer Device CSTD Sales Estimates and Forecasts (2021-2032)
2.4 Global Closed System Drug-Transfer Device CSTD Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Closed System Drug-Transfer Device CSTD Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Closed System Drug-Transfer Device CSTD Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Closed Vial Access Device: Market Share by Key Manufacturers
3.5.2 Closed Syringe Transfer Device: Market Share by Key Manufacturers
3.5.3 Closed Bag and Line Access Device: Market Share by Key Manufacturers
3.5.4 Integrated Closed Drug Transfer System: Market Share by Key Manufacturers
3.6 Global Closed System Drug-Transfer Device CSTD Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Closed System Drug-Transfer Device CSTD Sales Performance by Type
4.1.1 Global Closed System Drug-Transfer Device CSTD Sales Volume by Type (2021-2032)
4.1.2 Global Closed System Drug-Transfer Device CSTD Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Closed System Drug-Transfer Device CSTD Sales Performance by Technology Type
4.2.1 Global Closed System Drug-Transfer Device CSTD Sales Volume by Technology Type (2021-2032)
4.2.2 Global Closed System Drug-Transfer Device CSTD Revenue by Technology Type (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Technology Type (2021-2032)
4.3 Product Technology Differentiation
4.4 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.4.1 High-Growth Niches and Adoption Drivers
4.4.2 Profitability Hotspots and Cost Drivers
4.4.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Closed System Drug-Transfer Device CSTD Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Closed System Drug-Transfer Device CSTD Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Closed System Drug-Transfer Device CSTD Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Closed System Drug-Transfer Device CSTD Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Closed System Drug-Transfer Device CSTD Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Closed System Drug-Transfer Device CSTD Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Closed System Drug-Transfer Device CSTD Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Closed System Drug-Transfer Device CSTD Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Closed System Drug-Transfer Device CSTD Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Closed System Drug-Transfer Device CSTD Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Closed System Drug-Transfer Device CSTD Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Closed System Drug-Transfer Device CSTD Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Becton Dickinson and Company
11.1.1 Becton Dickinson and Company Corporation Information
11.1.2 Becton Dickinson and Company Business Overview
11.1.3 Becton Dickinson and Company Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.1.4 Becton Dickinson and Company Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Becton Dickinson and Company Closed System Drug-Transfer Device CSTD Sales by Product in 2025
11.1.6 Becton Dickinson and Company Closed System Drug-Transfer Device CSTD Sales by Application in 2025
11.1.7 Becton Dickinson and Company Closed System Drug-Transfer Device CSTD Sales by Geographic Area in 2025
11.1.8 Becton Dickinson and Company Closed System Drug-Transfer Device CSTD SWOT Analysis
11.1.9 Becton Dickinson and Company Recent Developments
11.2 ICU Medical Inc.
11.2.1 ICU Medical Inc. Corporation Information
11.2.2 ICU Medical Inc. Business Overview
11.2.3 ICU Medical Inc. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.2.4 ICU Medical Inc. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 ICU Medical Inc. Closed System Drug-Transfer Device CSTD Sales by Product in 2025
11.2.6 ICU Medical Inc. Closed System Drug-Transfer Device CSTD Sales by Application in 2025
11.2.7 ICU Medical Inc. Closed System Drug-Transfer Device CSTD Sales by Geographic Area in 2025
11.2.8 ICU Medical Inc. Closed System Drug-Transfer Device CSTD SWOT Analysis
11.2.9 ICU Medical Inc. Recent Developments
11.3 EQUASHIELD Medical Ltd.
11.3.1 EQUASHIELD Medical Ltd. Corporation Information
11.3.2 EQUASHIELD Medical Ltd. Business Overview
11.3.3 EQUASHIELD Medical Ltd. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.3.4 EQUASHIELD Medical Ltd. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 EQUASHIELD Medical Ltd. Closed System Drug-Transfer Device CSTD Sales by Product in 2025
11.3.6 EQUASHIELD Medical Ltd. Closed System Drug-Transfer Device CSTD Sales by Application in 2025
11.3.7 EQUASHIELD Medical Ltd. Closed System Drug-Transfer Device CSTD Sales by Geographic Area in 2025
11.3.8 EQUASHIELD Medical Ltd. Closed System Drug-Transfer Device CSTD SWOT Analysis
11.3.9 EQUASHIELD Medical Ltd. Recent Developments
11.4 Simplivia Healthcare Ltd.
11.4.1 Simplivia Healthcare Ltd. Corporation Information
11.4.2 Simplivia Healthcare Ltd. Business Overview
11.4.3 Simplivia Healthcare Ltd. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.4.4 Simplivia Healthcare Ltd. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Simplivia Healthcare Ltd. Closed System Drug-Transfer Device CSTD Sales by Product in 2025
11.4.6 Simplivia Healthcare Ltd. Closed System Drug-Transfer Device CSTD Sales by Application in 2025
11.4.7 Simplivia Healthcare Ltd. Closed System Drug-Transfer Device CSTD Sales by Geographic Area in 2025
11.4.8 Simplivia Healthcare Ltd. Closed System Drug-Transfer Device CSTD SWOT Analysis
11.4.9 Simplivia Healthcare Ltd. Recent Developments
11.5 Terumo Corporation
11.5.1 Terumo Corporation Corporation Information
11.5.2 Terumo Corporation Business Overview
11.5.3 Terumo Corporation Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.5.4 Terumo Corporation Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Terumo Corporation Closed System Drug-Transfer Device CSTD Sales by Product in 2025
11.5.6 Terumo Corporation Closed System Drug-Transfer Device CSTD Sales by Application in 2025
11.5.7 Terumo Corporation Closed System Drug-Transfer Device CSTD Sales by Geographic Area in 2025
11.5.8 Terumo Corporation Closed System Drug-Transfer Device CSTD SWOT Analysis
11.5.9 Terumo Corporation Recent Developments
11.6 JMS Co. Ltd.
11.6.1 JMS Co. Ltd. Corporation Information
11.6.2 JMS Co. Ltd. Business Overview
11.6.3 JMS Co. Ltd. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.6.4 JMS Co. Ltd. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 JMS Co. Ltd. Recent Developments
11.7 Vygon SAS
11.7.1 Vygon SAS Corporation Information
11.7.2 Vygon SAS Business Overview
11.7.3 Vygon SAS Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.7.4 Vygon SAS Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Vygon SAS Recent Developments
11.8 CODAN Medizinische Geräte GmbH
11.8.1 CODAN Medizinische Geräte GmbH Corporation Information
11.8.2 CODAN Medizinische Geräte GmbH Business Overview
11.8.3 CODAN Medizinische Geräte GmbH Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.8.4 CODAN Medizinische Geräte GmbH Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 CODAN Medizinische Geräte GmbH Recent Developments
11.9 Yukon Medical LLC
11.9.1 Yukon Medical LLC Corporation Information
11.9.2 Yukon Medical LLC Business Overview
11.9.3 Yukon Medical LLC Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.9.4 Yukon Medical LLC Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Yukon Medical LLC Recent Developments
11.10 CORMED Inc.
11.10.1 CORMED Inc. Corporation Information
11.10.2 CORMED Inc. Business Overview
11.10.3 CORMED Inc. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.10.4 CORMED Inc. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 CORMED Inc. Recent Developments
11.11 Epic Medical Pte. Ltd.
11.11.1 Epic Medical Pte. Ltd. Corporation Information
11.11.2 Epic Medical Pte. Ltd. Business Overview
11.11.3 Epic Medical Pte. Ltd. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.11.4 Epic Medical Pte. Ltd. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Epic Medical Pte. Ltd. Recent Developments
11.12 Haemopharm Healthcare S.r.l.
11.12.1 Haemopharm Healthcare S.r.l. Corporation Information
11.12.2 Haemopharm Healthcare S.r.l. Business Overview
11.12.3 Haemopharm Healthcare S.r.l. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.12.4 Haemopharm Healthcare S.r.l. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Haemopharm Healthcare S.r.l. Recent Developments
11.13 SIDAM S.r.l.
11.13.1 SIDAM S.r.l. Corporation Information
11.13.2 SIDAM S.r.l. Business Overview
11.13.3 SIDAM S.r.l. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.13.4 SIDAM S.r.l. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 SIDAM S.r.l. Recent Developments
11.14 Daiwa Can Company
11.14.1 Daiwa Can Company Corporation Information
11.14.2 Daiwa Can Company Business Overview
11.14.3 Daiwa Can Company Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.14.4 Daiwa Can Company Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Daiwa Can Company Recent Developments
11.15 Shinva Ande Healthcare Apparatus Co. Ltd.
11.15.1 Shinva Ande Healthcare Apparatus Co. Ltd. Corporation Information
11.15.2 Shinva Ande Healthcare Apparatus Co. Ltd. Business Overview
11.15.3 Shinva Ande Healthcare Apparatus Co. Ltd. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.15.4 Shinva Ande Healthcare Apparatus Co. Ltd. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Shinva Ande Healthcare Apparatus Co. Ltd. Recent Developments
11.16 Beijing Fert Technology Co. Ltd.
11.16.1 Beijing Fert Technology Co. Ltd. Corporation Information
11.16.2 Beijing Fert Technology Co. Ltd. Business Overview
11.16.3 Beijing Fert Technology Co. Ltd. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.16.4 Beijing Fert Technology Co. Ltd. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Beijing Fert Technology Co. Ltd. Recent Developments
11.17 Wuhan W.E.O. Science and Technology Development Co. Ltd.
11.17.1 Wuhan W.E.O. Science and Technology Development Co. Ltd. Corporation Information
11.17.2 Wuhan W.E.O. Science and Technology Development Co. Ltd. Business Overview
11.17.3 Wuhan W.E.O. Science and Technology Development Co. Ltd. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.17.4 Wuhan W.E.O. Science and Technology Development Co. Ltd. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 Wuhan W.E.O. Science and Technology Development Co. Ltd. Recent Developments
11.18 CHI FENG CO. LTD.
11.18.1 CHI FENG CO. LTD. Corporation Information
11.18.2 CHI FENG CO. LTD. Business Overview
11.18.3 CHI FENG CO. LTD. Closed System Drug-Transfer Device CSTD Product Models, Descriptions and Specifications
11.18.4 CHI FENG CO. LTD. Closed System Drug-Transfer Device CSTD Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 CHI FENG CO. LTD. Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Closed System Drug-Transfer Device CSTD Industry Chain
12.2 Closed System Drug-Transfer Device CSTD Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Closed System Drug-Transfer Device CSTD Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Closed System Drug-Transfer Device CSTD Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Closed System Drug-Transfer Device CSTD Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Closed System Drug-Transfer Device CSTD Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Closed System Drug-Transfer Device CSTD Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Closed System Drug-Transfer Device CSTD Market Size Growth Rate by Technology Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Closed System Drug-Transfer Device CSTD Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Closed System Drug-Transfer Device CSTD Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Closed System Drug-Transfer Device CSTD Revenue by Region (US$ Million), 2021-2026
Table 6. Global Closed System Drug-Transfer Device CSTD Revenue by Region (US$ Million), 2027-2032
Table 7. Global Closed System Drug-Transfer Device CSTD Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Table 8. Global Closed System Drug-Transfer Device CSTD Sales by Region (K Units), 2021-2026
Table 9. Global Closed System Drug-Transfer Device CSTD Sales by Region (K Units), 2027-2032
Table 10. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 11. Global Closed System Drug-Transfer Device CSTD Sales by Manufacturers (K Units), 2021-2026
Table 12. Global Closed System Drug-Transfer Device CSTD Sales Share by Manufacturers (2021-2026)
Table 13. Global Closed System Drug-Transfer Device CSTD Revenue by Manufacturers (US$ Million), 2021-2026
Table 14. Global Closed System Drug-Transfer Device CSTD Revenue-Based Market Share by Manufacturers (2021-2026)
Table 15. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 16. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Closed System Drug-Transfer Device CSTD Revenue, 2025
Table 17. Global Closed System Drug-Transfer Device CSTD Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 18. Global Closed System Drug-Transfer Device CSTD Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026
Table 19. Key Manufacturers Closed System Drug-Transfer Device CSTD Manufacturing Base and Headquarters
Table 20. Global Closed System Drug-Transfer Device CSTD Market Concentration Ratio (CR5)
Table 21. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 22. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 23. Global Closed System Drug-Transfer Device CSTD Sales Volume by Type (K Units), 2021-2026
Table 24. Global Closed System Drug-Transfer Device CSTD Sales Volume by Type (K Units), 2027-2032
Table 25. Global Closed System Drug-Transfer Device CSTD Revenue by Type (US$ Million), 2021-2026
Table 26. Global Closed System Drug-Transfer Device CSTD Revenue by Type (US$ Million), 2027-2032
Table 27. Global Closed System Drug-Transfer Device CSTD Sales Volume by Technology Type (K Units), 2021-2026
Table 28. Global Closed System Drug-Transfer Device CSTD Sales Volume by Technology Type (K Units), 2027-2032
Table 29. Global Closed System Drug-Transfer Device CSTD Revenue by Technology Type (US$ Million), 2021-2026
Table 30. Global Closed System Drug-Transfer Device CSTD Revenue by Technology Type (US$ Million), 2027-2032
Table 31. Technical Specifications by Key Product Type
Table 32. Global Closed System Drug-Transfer Device CSTD Sales by Application (K Units), 2021-2026
Table 33. Global Closed System Drug-Transfer Device CSTD Sales by Application (K Units), 2027-2032
Table 34. Closed System Drug-Transfer Device CSTD High-Growth Sectors Demand CAGR (2026-2032)
Table 35. Global Closed System Drug-Transfer Device CSTD Revenue by Application (US$ Million), 2021-2026
Table 36. Global Closed System Drug-Transfer Device CSTD Revenue by Application (US$ Million), 2027-2032
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Closed System Drug-Transfer Device CSTD Growth Accelerators and Market Barriers
Table 40. North America Closed System Drug-Transfer Device CSTD Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 41. North America Closed System Drug-Transfer Device CSTD Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 42. Europe Closed System Drug-Transfer Device CSTD Growth Accelerators and Market Barriers
Table 43. Europe Closed System Drug-Transfer Device CSTD Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 44. Europe Closed System Drug-Transfer Device CSTD Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 45. Asia-Pacific Closed System Drug-Transfer Device CSTD Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Asia-Pacific Closed System Drug-Transfer Device CSTD Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 47. Asia-Pacific Closed System Drug-Transfer Device CSTD Growth Accelerators and Market Barriers
Table 48. Southeast Asia Closed System Drug-Transfer Device CSTD Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Central and South America Closed System Drug-Transfer Device CSTD Investment Opportunities and Key Challenges
Table 50. Central and South America Closed System Drug-Transfer Device CSTD Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 51. Middle East and Africa Closed System Drug-Transfer Device CSTD Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Closed System Drug-Transfer Device CSTD Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 53. Becton Dickinson and Company Corporation Information
Table 54. Becton Dickinson and Company Description and Major Businesses
Table 55. Becton Dickinson and Company Product Models, Descriptions and Specifications
Table 56. Becton Dickinson and Company Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 57. Becton Dickinson and Company Sales Value Proportion by Product in 2025
Table 58. Becton Dickinson and Company Sales Value Proportion by Application in 2025
Table 59. Becton Dickinson and Company Sales Value Proportion by Geographic Area in 2025
Table 60. Becton Dickinson and Company Closed System Drug-Transfer Device CSTD SWOT Analysis
Table 61. Becton Dickinson and Company Recent Developments
Table 62. ICU Medical Inc. Corporation Information
Table 63. ICU Medical Inc. Description and Major Businesses
Table 64. ICU Medical Inc. Product Models, Descriptions and Specifications
Table 65. ICU Medical Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. ICU Medical Inc. Sales Value Proportion by Product in 2025
Table 67. ICU Medical Inc. Sales Value Proportion by Application in 2025
Table 68. ICU Medical Inc. Sales Value Proportion by Geographic Area in 2025
Table 69. ICU Medical Inc. Closed System Drug-Transfer Device CSTD SWOT Analysis
Table 70. ICU Medical Inc. Recent Developments
Table 71. EQUASHIELD Medical Ltd. Corporation Information
Table 72. EQUASHIELD Medical Ltd. Description and Major Businesses
Table 73. EQUASHIELD Medical Ltd. Product Models, Descriptions and Specifications
Table 74. EQUASHIELD Medical Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. EQUASHIELD Medical Ltd. Sales Value Proportion by Product in 2025
Table 76. EQUASHIELD Medical Ltd. Sales Value Proportion by Application in 2025
Table 77. EQUASHIELD Medical Ltd. Sales Value Proportion by Geographic Area in 2025
Table 78. EQUASHIELD Medical Ltd. Closed System Drug-Transfer Device CSTD SWOT Analysis
Table 79. EQUASHIELD Medical Ltd. Recent Developments
Table 80. Simplivia Healthcare Ltd. Corporation Information
Table 81. Simplivia Healthcare Ltd. Description and Major Businesses
Table 82. Simplivia Healthcare Ltd. Product Models, Descriptions and Specifications
Table 83. Simplivia Healthcare Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Simplivia Healthcare Ltd. Sales Value Proportion by Product in 2025
Table 85. Simplivia Healthcare Ltd. Sales Value Proportion by Application in 2025
Table 86. Simplivia Healthcare Ltd. Sales Value Proportion by Geographic Area in 2025
Table 87. Simplivia Healthcare Ltd. Closed System Drug-Transfer Device CSTD SWOT Analysis
Table 88. Simplivia Healthcare Ltd. Recent Developments
Table 89. Terumo Corporation Corporation Information
Table 90. Terumo Corporation Description and Major Businesses
Table 91. Terumo Corporation Product Models, Descriptions and Specifications
Table 92. Terumo Corporation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Terumo Corporation Sales Value Proportion by Product in 2025
Table 94. Terumo Corporation Sales Value Proportion by Application in 2025
Table 95. Terumo Corporation Sales Value Proportion by Geographic Area in 2025
Table 96. Terumo Corporation Closed System Drug-Transfer Device CSTD SWOT Analysis
Table 97. Terumo Corporation Recent Developments
Table 98. JMS Co. Ltd. Corporation Information
Table 99. JMS Co. Ltd. Description and Major Businesses
Table 100. JMS Co. Ltd. Product Models, Descriptions and Specifications
Table 101. JMS Co. Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. JMS Co. Ltd. Recent Developments
Table 103. Vygon SAS Corporation Information
Table 104. Vygon SAS Description and Major Businesses
Table 105. Vygon SAS Product Models, Descriptions and Specifications
Table 106. Vygon SAS Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Vygon SAS Recent Developments
Table 108. CODAN Medizinische Geräte GmbH Corporation Information
Table 109. CODAN Medizinische Geräte GmbH Description and Major Businesses
Table 110. CODAN Medizinische Geräte GmbH Product Models, Descriptions and Specifications
Table 111. CODAN Medizinische Geräte GmbH Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. CODAN Medizinische Geräte GmbH Recent Developments
Table 113. Yukon Medical LLC Corporation Information
Table 114. Yukon Medical LLC Description and Major Businesses
Table 115. Yukon Medical LLC Product Models, Descriptions and Specifications
Table 116. Yukon Medical LLC Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Yukon Medical LLC Recent Developments
Table 118. CORMED Inc. Corporation Information
Table 119. CORMED Inc. Description and Major Businesses
Table 120. CORMED Inc. Product Models, Descriptions and Specifications
Table 121. CORMED Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. CORMED Inc. Recent Developments
Table 123. Epic Medical Pte. Ltd. Corporation Information
Table 124. Epic Medical Pte. Ltd. Description and Major Businesses
Table 125. Epic Medical Pte. Ltd. Product Models, Descriptions and Specifications
Table 126. Epic Medical Pte. Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Epic Medical Pte. Ltd. Recent Developments
Table 128. Haemopharm Healthcare S.r.l. Corporation Information
Table 129. Haemopharm Healthcare S.r.l. Description and Major Businesses
Table 130. Haemopharm Healthcare S.r.l. Product Models, Descriptions and Specifications
Table 131. Haemopharm Healthcare S.r.l. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Haemopharm Healthcare S.r.l. Recent Developments
Table 133. SIDAM S.r.l. Corporation Information
Table 134. SIDAM S.r.l. Description and Major Businesses
Table 135. SIDAM S.r.l. Product Models, Descriptions and Specifications
Table 136. SIDAM S.r.l. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. SIDAM S.r.l. Recent Developments
Table 138. Daiwa Can Company Corporation Information
Table 139. Daiwa Can Company Description and Major Businesses
Table 140. Daiwa Can Company Product Models, Descriptions and Specifications
Table 141. Daiwa Can Company Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Daiwa Can Company Recent Developments
Table 143. Shinva Ande Healthcare Apparatus Co. Ltd. Corporation Information
Table 144. Shinva Ande Healthcare Apparatus Co. Ltd. Description and Major Businesses
Table 145. Shinva Ande Healthcare Apparatus Co. Ltd. Product Models, Descriptions and Specifications
Table 146. Shinva Ande Healthcare Apparatus Co. Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Shinva Ande Healthcare Apparatus Co. Ltd. Recent Developments
Table 148. Beijing Fert Technology Co. Ltd. Corporation Information
Table 149. Beijing Fert Technology Co. Ltd. Description and Major Businesses
Table 150. Beijing Fert Technology Co. Ltd. Product Models, Descriptions and Specifications
Table 151. Beijing Fert Technology Co. Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Beijing Fert Technology Co. Ltd. Recent Developments
Table 153. Wuhan W.E.O. Science and Technology Development Co. Ltd. Corporation Information
Table 154. Wuhan W.E.O. Science and Technology Development Co. Ltd. Description and Major Businesses
Table 155. Wuhan W.E.O. Science and Technology Development Co. Ltd. Product Models, Descriptions and Specifications
Table 156. Wuhan W.E.O. Science and Technology Development Co. Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Wuhan W.E.O. Science and Technology Development Co. Ltd. Recent Developments
Table 158. CHI FENG CO. LTD. Corporation Information
Table 159. CHI FENG CO. LTD. Description and Major Businesses
Table 160. CHI FENG CO. LTD. Product Models, Descriptions and Specifications
Table 161. CHI FENG CO. LTD. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. CHI FENG CO. LTD. Recent Developments
Table 163. Key Raw Materials Distribution
Table 164. Raw Materials Key Suppliers
Table 165. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 166. Milestones in Production Technology Evolution
Table 167. Distributors List
Table 168. Market Trends and Market Evolution
Table 169. Market Drivers and Opportunities
Table 170. Market Challenges, Risks, and Restraints
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources

List of Figures
Figure 1. Closed System Drug-Transfer Device CSTD Product Picture
Figure 2. Global Closed System Drug-Transfer Device CSTD Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Closed Vial Access Device Product Picture
Figure 4. Closed Syringe Transfer Device Product Picture
Figure 5. Closed Bag and Line Access Device Product Picture
Figure 6. Integrated Closed Drug Transfer System Product Picture
Figure 7. Global Closed System Drug-Transfer Device CSTD Market Size Growth Rate by Technology Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Physical Barrier Technology Product Picture
Figure 9. Air Cleaning Technology Product Picture
Figure 10. Other Product Picture
Figure 11. Global Closed System Drug-Transfer Device CSTD Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Oncology Drug Compounding
Figure 13. Oncology Infusion Administration
Figure 14. Hazardous Drug Pharmacy Preparation
Figure 15. Ambulatory Infusion Center
Figure 16. Other
Figure 17. Closed System Drug-Transfer Device CSTD Report Years Considered
Figure 18. Global Closed System Drug-Transfer Device CSTD Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 19. Global Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 20. Global Closed System Drug-Transfer Device CSTD Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Global Closed System Drug-Transfer Device CSTD Revenue-Based Market Share by Region (2021-2032)
Figure 22. Global Closed System Drug-Transfer Device CSTD Sales (K Units), 2021-2032
Figure 23. Global Closed System Drug-Transfer Device CSTD Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Figure 24. Global Closed System Drug-Transfer Device CSTD Sales Market Share by Region (2021-2032)
Figure 25. Top 5 and Top 10 Manufacturers Closed System Drug-Transfer Device CSTD Sales Volume Market Share in 2025
Figure 26. Global Closed System Drug-Transfer Device CSTD Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. Closed Vial Access Device Revenue-Based Market Share by Manufacturer in 2025
Figure 29. Closed Syringe Transfer Device Revenue-Based Market Share by Manufacturer in 2025
Figure 30. Closed Bag and Line Access Device Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Integrated Closed Drug Transfer System Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Global Closed System Drug-Transfer Device CSTD Sales Volume-Based Market Share by Type (2021-2032)
Figure 33. Global Closed System Drug-Transfer Device CSTD Revenue-Based Market Share by Type (2021-2032)
Figure 34. Global Closed System Drug-Transfer Device CSTD ASP by Type (US$/Unit), 2021-2032
Figure 35. Global Closed System Drug-Transfer Device CSTD Sales Volume-Based Market Share by Technology Type (2021-2032)
Figure 36. Global Closed System Drug-Transfer Device CSTD Revenue-Based Market Share by Technology Type (2021-2032)
Figure 37. Global Closed System Drug-Transfer Device CSTD ASP by Technology Type (US$/Unit), 2021-2032
Figure 38. Global Closed System Drug-Transfer Device CSTD Revenue-Based Market Share (2021-2032)
Figure 39. Global Closed System Drug-Transfer Device CSTD Sales Market Share by Application (2021-2032)
Figure 40. Global Closed System Drug-Transfer Device CSTD Revenue-Based Market Share by Application (2021-2032)
Figure 41. Global Closed System Drug-Transfer Device CSTD ASP by Application (US$/Unit), 2021-2032
Figure 42. North America Closed System Drug-Transfer Device CSTD Sales YoY (K Units), 2021-2032
Figure 43. North America Closed System Drug-Transfer Device CSTD Revenue YoY (US$ Million), 2021-2032
Figure 44. North America Top 5 Manufacturers Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) in 2025
Figure 45. North America Closed System Drug-Transfer Device CSTD Sales Volume (K Units) by Application (2021-2032)
Figure 46. North America Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) by Application (2021-2032)
Figure 47. US Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 48. Canada Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 49. Mexico Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 50. Europe Closed System Drug-Transfer Device CSTD Sales YoY (K Units), 2021-2032
Figure 51. Europe Closed System Drug-Transfer Device CSTD Revenue YoY (US$ Million), 2021-2032
Figure 52. Europe Top 5 Manufacturers Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) in 2025
Figure 53. Europe Closed System Drug-Transfer Device CSTD Sales Volume (K Units) by Application (2021-2032)
Figure 54. Europe Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) by Application (2021-2032)
Figure 55. Germany Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 56. France Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 57. U.K. Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 58. Italy Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 59. Russia Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 60. Asia-Pacific Closed System Drug-Transfer Device CSTD Sales YoY (K Units), 2021-2032
Figure 61. Asia-Pacific Closed System Drug-Transfer Device CSTD Revenue YoY (US$ Million), 2021-2032
Figure 62. Asia-Pacific Top 8 Manufacturers Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) in 2025
Figure 63. Asia-Pacific Closed System Drug-Transfer Device CSTD Sales Volume (K Units) by Application (2021-2032)
Figure 64. Asia-Pacific Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) by Application (2021-2032)
Figure 65. Indonesia Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 66. Japan Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 67. South Korea Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 68. China Taiwan Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 69. India Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 70. Central and South America Closed System Drug-Transfer Device CSTD Sales YoY (K Units), 2021-2032
Figure 71. Central and South America Closed System Drug-Transfer Device CSTD Revenue YoY (US$ Million), 2021-2032
Figure 72. Central and South America Top 5 Manufacturers Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) in 2025
Figure 73. Central and South America Closed System Drug-Transfer Device CSTD Sales Volume (K Units) by Application (2021-2032)
Figure 74. Central and South America Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) by Application (2021-2032)
Figure 75. Brazil Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 76. Argentina Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 77. Middle East, and Africa Closed System Drug-Transfer Device CSTD Sales YoY (K Units), 2021-2032
Figure 78. Middle East and Africa Closed System Drug-Transfer Device CSTD Revenue YoY (US$ Million), 2021-2032
Figure 79. Middle East and Africa Top 5 Manufacturers Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) in 2025
Figure 80. Middle East and Africa Closed System Drug-Transfer Device CSTD Sales Volume (K Units) by Application (2021-2032)
Figure 81. Middle East and Africa Closed System Drug-Transfer Device CSTD Sales Revenue (US$ Million) by Application (2021-2032)
Figure 82. GCC Countries Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 83. Turkey Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 84. Egypt Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 85. South Africa Closed System Drug-Transfer Device CSTD Revenue (US$ Million), 2021-2032
Figure 86. Closed System Drug-Transfer Device CSTD Industry Chain Mapping
Figure 87. Regional Closed System Drug-Transfer Device CSTD Manufacturing Base Distribution (%)
Figure 88. Global Closed System Drug-Transfer Device CSTD Production Market Share by Region (2021-2032)
Figure 89. Closed System Drug-Transfer Device CSTD Production Process
Figure 90. Regional Closed System Drug-Transfer Device CSTD Production Cost Structure
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed